Celgene's Blockbuster Disappoints Wall Street

Sales of the drugmaker's blood cancer compound may have nearly doubled, but that wasn't enough for investors, who sold off the stock Thursday

With high hopes come high expectations. That's what Celgene (CELG) found out when it released its third quarter earnings report Oct. 25.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.